NCT06302205 A Home-based Exercise and Physical Activity Intervention After Liver Transplantation: Impact of Exercise Intensity
| NCT ID | NCT06302205 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Condition | Liver Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 147 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2026-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 147 participants in total. It began in 2023-03-01 with a primary completion date of 2026-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research demonstrated that transplant recipients benefit from physical activity, but there is a gap in knowledge regarding the required intensity. In the PHOENIX-Liver study, researchers aim to investigate the adequate intensity of rehabilitation programs after liver transplantation. Patients will be randomized into one of the three PHOENIX-Liver training groups (low, moderate, moderate to high). The six months rehabilitation program is conducted from the patient's home but supervised by a PHOENIX-investigator. At baseline, after three months of rehabilitation and after six months of rehabilitation, a test moment takes place at which physical fitness, cardiovascular health, liver function, and body composition will be assessed. Questionnaires are taken monthly to survey well-being, safety, quality of life, physical activity, and cost-effectiveness. To gather information on the potential for implementation in a real-world setting, a 15-month-long physical activity phase will start after the intervention phase. This entails a maintenance physical activity program tailored to the patients' preferences. A follow-up at UZ Leuven is planned at three and at 15 months where the same clinical evaluations will be conducted as during the test moments of the intervention phase.
Eligibility Criteria
Inclusion Criteria: * de novo adult liver transplant recipients with a transplant vintage of two to three months * access to a home freezer (± -18°C) Exclusion Criteria: * Aberrant CPET (abnormal low cardiorespiratory fitness is not considered an exclusion criteria), unstable angina, life-threatening arrhythmias, uncontrolled hypertension/diabetes, HbA1c ≥ 9%, severe pulmonary disease (FEV1 \< 50%), musculoskeletal disorders not allowing physical training on a cycle ergometer, or any other medical reasons by the physician considered to be a contraindication for moderate or high-intensity physical exercise * multi-organ transplantation (exception: combined liver-kidney transplant is considered eligible for participation) * ongoing treatment for malignancies * unable to understand Dutch * no access to smartphone and/or computer with internet access * does not willing to except the general conditions of Coachbox. Preparticipation medical screening (cardiopulmonary exercise testing with 12-lead ECG + stratification of cardiovascular risk factors) will be performed by a cardiologist (Dr. Kaatje Goetschalckx at UZ Leuven).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06302205 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06302205 currently recruiting?
Yes, NCT06302205 is actively recruiting participants. Contact the research team at diethard.monbaliu@uzleuven.be for enrollment information.
Where is the NCT06302205 trial being conducted?
This trial is being conducted at Leuven, Belgium.
Who is sponsoring the NCT06302205 clinical trial?
NCT06302205 is sponsored by Universitaire Ziekenhuizen KU Leuven. The trial plans to enroll 147 participants.